VEGFA and renal cell carcinoma: Sorafenib is the oral multi-kinase inhibitor that targets Raf, mast/stem cell growth factor receptor (c-KIT), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) receptor tyrosine kinase signaling transduction and is used for the treatment of hepatocellular carcinoma (HCC), renal cell carcinoma, and differentiated thyroid cancer [6,7].